PEMF for Delayed and Non-Union Fractures: What the Clinical Evidence Shows

Most fractures heal with appropriate stabilization, sufficient blood supply and time. A smaller proportion develop delayed union or non-union, where bone healing slows significantly or fails to progress as expected.

Pulsed Electromagnetic Field therapy, usually shortened to PEMF, is one of the most established non-invasive technologies investigated for these difficult-to-heal fractures. It uses external coils to generate time-varying electromagnetic fields that pass through soft tissue and reach the fracture site without surgery, implanted electrodes or significant heating.

For medical-device brands, bone healing is also one of the most clinically developed applications of PEMF. The evidence, however, is not equally strong across every bone-health indication.

Research is most convincing in delayed and non-union fractures. Evidence for routinely accelerating otherwise normal acute fracture healing is considerably weaker, while research into osteoporosis and bone mineral density remains more mixed.

That distinction matters during product development. Intended use influences the treatment parameters, form factor, evidence strategy, regulatory pathway and claims that can ultimately be supported.

For a broader overview of the technology and potential device formats, see PEMF Technology.

What is PEMF and how is it used in orthopaedics?

PEMF systems use coils to generate pulsed electromagnetic fields around a targeted treatment area. These fields pass through clothing and soft tissue, allowing treatment to be delivered without direct electrical contact with the fracture itself.

Unlike EMS, PEMF is not designed to produce visible muscle contraction. At the treatment levels used for bone-healing applications, the user may feel little or nothing during a session.

The technology has a long history in orthopaedics. PEMF received authorization in the United States for the treatment of bone non-unions as far back as 1979, making fracture healing one of its most established medical applications.

This history is important for OEMs because it separates bone-healing PEMF from many broader wellness applications. There is an existing clinical and regulatory foundation, but products still need to be developed around a specific intended use and validated treatment protocol.

For brands considering development in this category, our PEMF Manufacturer page provides an overview of LTT's OEM and private-label approach.

How could PEMF influence bone healing?

PEMF does not mechanically reposition or stabilize a fracture. Instead, it provides a biological stimulus around the healing tissue.

Laboratory research suggests electromagnetic stimulation can influence osteoblasts, the cells responsible for producing new bone, as well as signalling pathways involved in bone formation and tissue organization.

Research has investigated effects on adenosine receptor signalling, osteoblast differentiation and pathways such as Wnt and beta-catenin, which play roles in bone growth and repair.

These mechanisms provide a plausible explanation for why electromagnetic fields could support fracture healing.

They should not, however, be confused with clinical proof.

A biological effect observed in cells or laboratory models does not automatically mean a device will improve fracture healing in patients. The clinical question can only be answered by looking at human outcomes.

What does the clinical evidence show for delayed and non-union fractures?

This is where the PEMF evidence is strongest.

Clinical research has reported meaningful union rates in patients whose fractures were healing slowly or had failed to unite.

One prospective study involving 44 patients with tibial delayed unions or non-unions reported confirmed healing in 77.3 percent of those receiving PEMF treatment.

Across reviews of non-union studies, reported healing rates are commonly in the range of approximately 70 to 85 percent, although study quality, treatment protocols and patient populations vary considerably.

Research in delayed long-bone fractures has also produced encouraging results. One comparison reported union in 77.4 percent of patients receiving PEMF compared with 48.1 percent in the sham group.

A systematic review of 22 randomized trials involving 1,468 participants reported moderate-quality evidence that PEMF improved fracture-healing rates and reduced pain. Healing occurred in approximately 79.7 percent of PEMF groups compared with 64.3 percent of control groups.

These figures should not be interpreted as a guaranteed success rate for every PEMF device.

Fracture location, mechanical stability, patient health and treatment adherence all influence the probability of healing. Different studies also use different frequencies, field strengths and treatment schedules.

The more important conclusion is that the evidence base is substantially stronger for delayed and non-union fractures than for routine acute fracture healing.

For OEMs, that makes delayed and non-union fractures the more defensible clinical use case when developing a focused bone-healing product.

Why mechanical stability still matters

PEMF can provide a biological stimulus, but biology is only one part of fracture healing.

The fracture also needs sufficient mechanical stability.

If a fracture is moving excessively, poorly aligned or inadequately fixed, electromagnetic stimulation cannot compensate for the mechanical problem.

The same applies to infection, severe vascular compromise or other biological barriers to healing.

This is why PEMF should be positioned as an adjunct to appropriate orthopaedic care rather than as a replacement for fracture reduction, fixation or surgery where these are required.

For product developers, that distinction influences not only marketing but also the intended-use statement and patient-selection criteria.

What does the evidence show for acute fractures?

The picture becomes less convincing when PEMF is applied routinely to fresh fractures that are already healing normally.

Recent systematic reviews of randomized controlled trials have not found consistent evidence that PEMF significantly improves healing in acute fractures compared with control treatment.

Earlier reviews reached similar conclusions, finding insufficient evidence that electromagnetic stimulation prevents non-unions when used routinely after a new fracture.

This suggests that the clinical value of PEMF may be greater when the normal healing process has slowed or stalled rather than when the body is already progressing through fracture repair as expected.

That is an important commercial distinction.

A device positioned around all fractures has a much broader claim than one specifically developed for delayed or non-union healing. The broader proposition therefore requires evidence that the current literature does not support as consistently.

What about osteoporosis and bone density?

PEMF has also been investigated for bone mineral density and osteoporosis.

Meta-analyses involving more than 1,300 participants have reported improvements in bone mineral density at several skeletal sites when PEMF was used, particularly when combined with conventional treatment.

Research in postmenopausal women has reported similar findings, although effects have not been consistent across all anatomical locations.

Some reviews suggest PEMF may produce outcomes comparable with exercise or conventional therapies for selected bone-density measurements in older adults.

The limitations are significant.

Much of the available evidence has been rated as moderate to very low certainty, follow-up periods are often relatively short and improvements in bone mineral density are not the same as demonstrating a reduction in fracture risk.

The evidence for localized fracture-healing applications is therefore more established than the evidence for using PEMF as a general bone-strengthening or osteoporosis technology.

For OEMs, these should be treated as separate indications with different evidence requirements rather than grouped together under a broad “bone health” claim.

Treatment parameters remain an important question

Even within delayed and non-union fracture research, there is no single universal PEMF protocol.

Studies differ in:

• Frequency
• Field strength
• Waveform
• Pulse pattern
• Treatment duration
• Daily exposure time
• Total treatment period

This variation makes it difficult to identify one universally optimal dose.

That uncertainty is particularly relevant for product development.

An OEM cannot simply select a technically convenient electromagnetic output and assume that published PEMF evidence applies to it. The device parameters need to be connected to the literature supporting the intended application.

The same principle applies in other energy-based therapies. Hardware specifications only become meaningful when they are linked to the biological target and treatment protocol.

Adherence can influence clinical outcomes

Bone-healing PEMF often requires repeated use over an extended period.

That makes adherence part of the product's effectiveness.

A device may have technically appropriate parameters but still perform poorly in practice if it is uncomfortable, inconvenient or difficult to position correctly for the required number of hours.

This creates several important engineering questions.

How easily can the coil be positioned over the fracture? Can the system remain comfortable during prolonged daily use? How heavy is the device? How often does it need charging? Can treatment time be recorded?

Connected systems may help by tracking treatment duration, reminding users when sessions are missed or allowing clinicians to review adherence.

These features should not be added simply because app connectivity is possible. Their value lies in helping users follow the protocol that supports the intended clinical outcome.

Form factor should follow the fracture application

A PEMF system intended for a tibial fracture has different physical requirements from one designed for the wrist, foot or another anatomical location.

Coil geometry affects how the electromagnetic field is delivered to the treatment area. The physical interface also needs to accommodate casts, braces or other orthopaedic equipment that may already be present.

For OEMs, important design variables include:

• Coil size and geometry
• Placement repeatability
• Fixation around the treatment area
• Device weight
• Battery capacity
• Portability
• Comfort during prolonged wear

The objective is not simply to create a magnetic field.

The system needs to deliver that field consistently to the intended anatomical area while remaining practical enough for repeated use.

Safety and contraindications

PEMF is non-invasive and is generally described as well tolerated in the bone-healing literature.

That does not remove the need for a clear safety strategy.

As with other active medical devices, patient screening should reflect the intended use and final technical design. Users with implanted electronic devices or specific medical conditions may require additional precautions or medical guidance.

The product also needs clear instructions around placement, duration of use and situations where treatment should be stopped or reviewed by a clinician.

Safety requirements should therefore be developed alongside the electromagnetic parameters rather than added to the instructions after engineering is complete.

What PEMF cannot do

Clear limitations improve product credibility.

PEMF does not mechanically reduce a fracture or provide structural stability. It cannot replace appropriate fixation, surgery or weight-bearing protocols where these are clinically required.

The evidence also does not show that PEMF reliably accelerates every normally healing acute fracture.

Nor should bone-healing PEMF automatically be positioned as a general osteoporosis treatment or a way to strengthen healthy bones.

These are different clinical propositions.

A focused indication is easier to support scientifically, clinically and commercially than a device claiming to improve every aspect of bone health.

What this means for PEMF device development

The clinical evidence points towards a focused development strategy.

The first decision is intended use.

A product for delayed and non-union fractures should not be developed in the same way as a general wellness PEMF mat. The hardware, clinical evidence and regulatory expectations are fundamentally different.

Once the intended use is defined, several decisions follow.

Treatment parameters

The waveform, frequency, field strength and pulse characteristics should be linked to the evidence supporting the intended application.

Treatment duration

Daily exposure and total treatment period need to reflect the therapeutic protocol while remaining realistic for the patient.

Form factor

The coil system needs to fit the intended anatomical area and remain comfortable enough for repeated use.

Adherence

When treatment requires weeks or months of regular use, the device should make compliance easier rather than adding another burden to recovery.

Evidence strategy

Published literature may support the scientific rationale, but the evidence needs to match the final product closely enough to substantiate its claims. Depending on the intended use and regulatory pathway, product-specific testing or clinical evidence may also be required.

This is why clinical evidence and product development should progress together rather than as separate workstreams. We discuss this principle further in Clinical Evidence and Claims: What Device Brands Need to Know.

Regulatory strategy needs to start early

A device claiming to support healing of delayed or non-union fractures is clearly positioned within medical-device territory.

That creates requirements around quality management, risk management, technical documentation, verification, validation and clinical evidence.

The precise route depends on the target market and the finished product, but the underlying principle is consistent: the intended medical claim needs to be supported by the product's evidence and development process.

Quality systems such as ISO 13485 become particularly important because they connect design controls, supplier management, production and post-market processes.

For brands planning medical PEMF devices, regulatory strategy therefore needs to be defined before tooling and mass production.

Changing a wellness concept into a medical fracture-healing device late in development can require substantial redesign and additional validation.

PEMF compared with other bone-healing approaches

PEMF should be understood as a biological adjunct rather than a mechanical treatment.

It does not replace surgical fixation or established orthopaedic care. Its potential value lies in supporting the biological side of healing when progress has slowed.

That is also what makes the delayed and non-union application particularly relevant.

These are situations where the body has not completed the repair process as expected, making an additional biological stimulus more meaningful than in a fracture that is already healing normally.

For OEMs, this creates a clearer product proposition than broad consumer positioning.

The device is designed for a defined clinical problem, with parameters, evidence and usability built around that problem.

Conclusion

PEMF has one of the longest clinical histories among non-invasive technologies used to support bone healing.

The evidence is strongest for delayed and non-union fractures, where clinical studies and reviews have reported meaningful improvements in healing outcomes. The evidence for routine acute fracture healing is considerably weaker, while research into osteoporosis and bone mineral density remains less definitive.

For OEMs, the opportunity therefore lies in precision.

A strong PEMF bone-healing device starts with a defined patient group and intended use. From there, the electromagnetic parameters, form factor, adherence strategy, clinical evidence and regulatory pathway can be developed as one system.

The goal should not be to create a PEMF product with the broadest possible claims.

It should be to develop a device whose technical specifications and evidence align closely enough to support a credible clinical application.

At Light Tree Technology, we help brands develop PEMF technologies from early research and product definition through industrial design, engineering, prototyping, regulatory preparation and scalable manufacturing.

Looking to develop a PEMF bone-healing device?

Define the intended clinical application first, then build the parameters, product architecture and evidence strategy around it.

Start your project with Light Tree Technology.

References

Haress, Z. (2026). PEMF for Bone Healing: From Non-Union Fractures to Bone Density. Light Tree Technology.

Haress, Z. (2026). PEMF for Bone Health & Strength: Can Electromagnetic Fields Help Bone Repair? Light Tree Technology.

‍